Data from the SHOTZ study were compared showing the mechanisms of action of Forteo (teriparatide [rDNA origin] injection) from Eli...
Pfenex Inc. has announced that the FDA has approved the new drug application (�NDA�) for PF 708 submitted under the...
STADA Arzneimittel AG has received a positive opinion for the biosimilar teriparatide (originator drug Forteo/Forsteo from Eli Lilly) from the...
Radius Health, Inc. has announced that the FDA has approved Tymlos (abaloparatide) injection for the treatment of postmenopausal women with...
Amgen and UCB announced that the FDA has issued a Complete Response Letter for the Biologics License Application (BLA) for...
Amgen and UCB announced top-line results from the STRUCTURE trial of AMG 785 (romosozumab) compared with teriparatide in postmenopausal women...
Amgen and UCB announced the resubmission of the Biologics License Application (BLA) to the FDA for Evenity (romosozumab), a monoclonal...
April 2016-Amgen and UCB announced detailed Phase III results showing the investigational agent romosozumab demonstrated a statistically significant increase in...
Amgen and UCB announced positive top-line results for AMG 785 (romosozumab) from the pivotal Phase III BRIDGE trial assessing the...